DISABILITY PROGRESSION IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCE DISEASE ACTIVITY DESPITE PREVIOUS DISEASE MODIFYING THERAPY

DISABILITY PROGRESSION IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCE DISEASE ACTIVITY DESPITE PREVIOUS DISEASE MODIFYING THERAPY

Bibliographic Details
Main Authors:	Hettle, R, Murphy, J, Eckert, B
Format:	Journal article
Published:	2011

Similar Items

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
by: Lesage, E, et al.
Published: (2010)

Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)
by: Silvia Ciotti, et al.
Published: (2021-02-01)

Increased Level of Caspase-1 in the Serum of Relapsing-remitting Multiple Sclerosis (RRMS) Patients
by: Masoumeh Beheshti, et al.
Published: (2020-10-01)

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments
by: Gutemberg Augusto Cruz dos Santos, et al.
Published: (2022-12-01)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
by: Feng J, et al.
Published: (2019-11-01)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
by: Fabricio Gonz&aacute;lez-Andrade, et al.
Published: (2010-07-01)

Serum Matrix Metalloproteinase-9 Level and Previous Disease Activity in Relapsing-Remitting Multiple Sclerosis
by: Eman Hamdy, et al.
Published: (2023-01-01)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
by: Magdalena Chylińska, et al.
Published: (2023-01-01)

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01)

Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression
by: Laura Barcutean, et al.
Published: (2024-03-01)

008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
by: Steve Vucic, et al.
Published: (2021-08-01)

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
by: Georgios Tsivgoulis, et al.
Published: (2015-01-01)

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
by: Katline Metzger-Peter, et al.
Published: (2020-06-01)

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents
by: Alessandro Finkelsztejn, et al.
Published: (2012-10-01)

Early clinical predictors of disease progression in relapsing-remitting multiple sclerosis: the Oxford UK cohort
by: Wakerley, B, et al.
Published: (2011)

Interferons in relapsing remitting multiple sclerosis.
by: Goodin, D
Published: (2003)

Natalizumab for relapsing-remitting multiple sclerosis
by: A. Horga, et al.
Published: (2011-01-01)

Does the type of disease-modifying drugs impact on the quality of life in patients with relapsing-remitting multiple sclerosis?
by: Amirreza Naseri, et al.
Published: (2020-09-01)

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
by: Iciar Martínez-López, et al.
Published: (2020-04-01)

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
by: Oscar Fernández, et al.
Published: (2017-01-01)

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
by: J. Nicholas, et al.
Published: (2012-05-01)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
by: Pierre Branger, et al.
Published: (2016-01-01)

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis
by: Ahmad, H, et al.
Published: (2018)

Red cell distribution width as a predictor of disability in relapsing-remitting multiple sclerosis
by: R. Rocha, et al.
Published: (2022-04-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
by: V. Casado, et al.
Published: (2021-07-01)

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis
by: Linda Östlundh, et al.
Published: (2023-07-01)

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
by: Emanuele D’Amico, et al.
Published: (2019-09-01)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
by: Cifelli, A, et al.
Published: (2003)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
by: Wylezinska, M, et al.
Published: (2003)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01)

Cognitive impairment in relapsing remitting Multiple Sclerosis
by: Saška Roškar
Published: (2003-06-01)

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
by: Anna Bizoń, et al.
Published: (2022-12-01)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
by: Daniel Kantor, et al.
Published: (2023-03-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01)

Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.
by: Marcel P Stoop, et al.
Published: (2010-01-01)

Intrinsic functional plasticity of the thalamocortical system in minimally disabled patients with relapsing-remitting multiple sclerosis
by: Fuqing eZhou, et al.
Published: (2016-01-01)

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability
by: Mariacristina Siotto, et al.
Published: (2019-02-01)

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability
by: Arzu Ceylan Has Silemek, et al.
Published: (2020-01-01)